Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
aTyr Pharma, Inc. Market Cap
Based on ratings from 7 stock analysts, the aTyr Pharma, Inc. stock price is expected to increase by 502.99% in 12 months. This is calculated by using the average 12-month stock price forecast for aTyr Pharma, Inc.. The lowest target is $9 and the highest is $35. Please note analyst price targets are not guaranteed and could be missed completely.
ATYR is a stock in Healthcare which has been forecasted to be worth $21.28571 as an average. On the higher end, the forecast price is $35 USD by Joseph Pantginis from HC Wainwright & Co. and on the lower end ATYR is forecasted to be $9 by Roger Song from Jefferies.
These are the latest 20 analyst ratings of ATYR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Pantginis HC Wainwright & Co. | Buy | $35 | Reiterates | Oct 29, 2024 |
| Derek Archila Wells Fargo | Overweight | $17 | Initiates | Oct 4, 2024 |
| Roger Song Jefferies | Buy | $9 | Initiates | Sep 5, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $35 | Reiterates | Aug 15, 2024 |
| Gregory Renza RBC Capital | Outperform | $16 | Reiterates | Aug 14, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $35 | Reiterates | Aug 1, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $35 | Reiterates | Jul 22, 2024 |
HC Wainwright & Co. | Buy | Reiterates | May 14, 2024 | |
HC Wainwright & Co. | Buy | Reiterates | May 3, 2024 | |
RBC Capital | Outperform | Maintains | Mar 15, 2024 | |
HC Wainwright & Co. | Buy | Reiterates | Mar 15, 2024 | |
HC Wainwright & Co. | Buy | Reiterates | Feb 21, 2024 |
When did it IPO
2015
Staff Count
56
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Sanjay S. Shukla M.D., M.S.
Market Cap
$288.8M
In 2023, ATYR generated $353,000 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ATYR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 15 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - aTyr Pharma (Nasdaq: ATYR) will present two posters on its tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis from December 8-11, 2024, in Whistler, Canada.
Why It Matters - aTyr Pharma's presentation at a key scientific symposium highlights progress in its drug development, potentially increasing investor confidence and interest in its tRNA synthetase platform.
Thu, 24 Oct 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - aTyr Pharma's Efzofitimod shows promise for pulmonary sarcoidosis and SSC-ILD, with key trial readouts upcoming. The company has $81 million in cash and positive stock performance.
Why It Matters - aTyr Pharma's pivotal trials for Efzofitimod could unlock a large market, and strong funding along with insider buying signals confidence, potentially driving stock performance.
Mon, 14 Oct 2024
Sentiment - NEUTRAL
Source - Newsfile Corp
Summary - aTyr Pharma, Inc. (NASDAQ: ATYR) announced Sanjay S. Shukla, M.D. has joined the company. aTyr focuses on developing medicines from its tRNA synthetase platform.
Why It Matters - aTyr Pharma's leadership announcement may signal strategic shifts or new initiatives, impacting investor confidence and stock performance in the biotech sector.
Mon, 09 Sep 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Topline data from the phase 3 EFZO-FIT study on efzofitimod for pulmonary sarcoidosis is expected in Q3 2025. The market for pulmonary sarcoidosis is projected to reach $53.3 billion by 2034. Phase 2 data for scleroderma-related ILD is expected in Q2 2025.
Why It Matters - Upcoming phase 3 data on efzofitimod could signal significant market potential, with projected pulmonary sarcoidosis market growth to $53.3 billion by 2034, impacting investment valuations.
Wed, 21 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - aTyr Pharma, Inc. (Nasdaq: ATYR) will participate in investor conferences in September 2024, including the Wells Fargo Healthcare Conference on September 5 in Everett, MA.
Why It Matters - aTyr Pharma's participation in key investor conferences signals potential interest and updates on its drug development, which may influence stock performance and investor sentiment.
Tue, 13 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Enrollment for the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis is complete with 268 patients. Topline data is expected in Q3 2025. The company had $81.4 million in cash as of Q2 2024.
Why It Matters - Completion of patient enrollment for a key study could signal potential breakthroughs in treatment, impacting future revenue. Adequate cash reserves suggest financial stability for ongoing research.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
